149 Bio
AlloSite Tx is a biotechnology company focused on developing breakthrough medicines for kidney diseases, particularly lupus nephritis. Utilizing their proprietary AI-enabled CellStaple Platform, they identify novel antibody and small molecule therapeutics. Their lead product, ONT01, is a clinical-stage integrin CD11b agonist aimed at treating lupus nephritis. With a strong team led by experienced professionals, AlloSite is positioned to address significant unmet medical needs in the kidney disease market, which affects millions of patients in the U.S.
149 Bio
AlloSite Tx is a biotechnology company focused on developing breakthrough medicines for kidney diseases, particularly lupus nephritis. Utilizing their proprietary AI-enabled CellStaple Platform, they identify novel antibody and small molecule therapeutics. Their lead product, ONT01, is a clinical-stage integrin CD11b agonist aimed at treating lupus nephritis. With a strong team led by experienced professionals, AlloSite is positioned to address significant unmet medical needs in the kidney disease market, which affects millions of patients in the U.S.